ADVANCED CHILD PSYCHOPHARMACOLOGY · 2020-04-29 · 1 ADVANCED CHILD PSYCHOPHARMACOLOGY REFERENCES...
Transcript of ADVANCED CHILD PSYCHOPHARMACOLOGY · 2020-04-29 · 1 ADVANCED CHILD PSYCHOPHARMACOLOGY REFERENCES...
1
ADVANCED CHILD PSYCHOPHARMACOLOGY
REFERENCES
(Updated April 2017)
GENERAL REFERENCES:
Textbooks:
Connor DF, Meltzer BM (2006), Pediatric Psychopharmacology: Fast Facts. New York,
NY: W.W. Norton & Company
Elbe D, Bezchlibnyk-Butler KZ, Virani AS, Procyshyn RM eds. (2014), Clinical
Handbook of Psychotropic Drugs for Children and Adolescents. 3rd ed. Boston, MA:
Hogrefe Publishing
Findling RL ed (2013), Clinical Manual of Child and Adolescent Psychopharmacology.
2nd ed. Arlington, VA: American Psychiatric Publishing, Inc.
Klykylo W, Bowers R, Jackson J, Weston C (2013), Green’s Child & Adolescent Clinical
Psychopharmacology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins
Martin A, Scahill L, Kratochvil C eds. (2011), Pediatric Psychopharmacology:
Principles and Practice. 2nd ed. New York, NY: Oxford University Press
Martin A, Volkmar FR eds. (2007), Lewis's Child and Adolescent Psychiatry: A
Comprehensive Textbook. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins
Sadock BJ, Sadock VA, Ruiz P eds. (2017), Kaplan & Sadock’s Comprehensive
Textbook of Psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins
Journals
Journal of the American Academy of Child and Adolescent Psychiatry
Note that JAACAP has published a wide range of practice parameters:
www.aacap.org/cs/root/member_information/practice_information/practice_parameter
s/practice_parameters
Journal of the Canadian Academy of Child and Adolescent Psychiatry
Journal of Child and Adolescent Psychopharmacology
For Families and Teachers:
Dulcan MK, Ballard RR ed. (2015), Helping Parents and Teachers Understand
Medications for Behavioral and Emotional Problems: A Resource Book of Medication
Information Handouts. 4th ed. Arlington, VA: American Psychiatric Publishing, Inc.
Wilens TE, Hammerness PG (2016), Straight Talk about Psychiatric Medications for
Kids. 4th ed. New York: The Guilford Press.
= required reading = suggested reading 2
REFERENCES FOR SEMINARS:
Introductory Seminar: “Kids Aren’t Little Adults”
Credibility crisis in pediatric psychiatry (editorial, no authors given). Nat Neurosci 2008;
11:983.
Albert PR. Drugs for kids: good or bad? J Psychiatry Neurosci 2012; 37:293-5.
American Academy of Child & Adolescent Psychiatry. AACAP official action. Practice
parameters for the use of psychotropic medications in children and adolescents. J Am
Acad Child Adolesc Psychiatry 2009; 48:967-73.
Angell M. Drug companies & doctors: a story of corruption. The New York Review of
books, January 15, 2009.
Carlat D. Mind Over Meds. New York Times Magazine, April 19, 2010.
Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic
medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;
45:771-91.
Correll CU, Kratochvil CJ, March JS. Developments in pediatric
psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J
Clin Psychiatry 2011;72:655-70. (Read for second introductory seminar.)
Cowen PJ. Has psychopharmacology got a future? Br J Psychiatry 2011; 198:333-5.
Garcia G, Logan GE, Gonzalez-Heydrich J. Management of psychotropic medication
side effects in children and adolescents. Child Adolesc Psychiatric Clin N Am 2012;
21:713-38.
Ghaemi SN. Toward a Hippocratic psychopharmacology. Can J Psychiatry 2008;53:189-
96.
Olfson M, Druss BG, Marcus SC. Trends in mental health care among children and
adolescents. N Engl J Med 2015; 372:2029-38.
Pescosolido BA, Perry BL, Martin JK, McLeod JD, Jensen PS. Stigmatizing attitudes and
beliefs about treatment and psychiatric medications for children with mental illness.
Psychiatr Serv 2007; 58:613-8.
Pichini S, Papaseit E, Joya X, Vall O, Farre M, Garcia-Algar O, et al. Pharmacokinetics
and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit
2009; 31:283-318.
Rapoport JL. Pediatric psychopharmacology: too much or too little? World Psychiatry
2013; 12:118-23.
Smoller JW: The etiology and treatment of childhood. www.pfc.org.uk/node/595
1998. (Read for first introductory seminar.)
Stroeh O, Trivedi HK. Appropriate and judicious use of psychotropic medications in
youth. Child Adolesc Psychiatr Clin N Am 2012; 21:703-11.
= required reading = suggested reading 3
Vitiello B. Developmental aspects of pediatric psychopharmacology. In: Findling RL, ed.
Clinical Manual of Child and Adolescent Psychopharmacology. Arlington, VA:
American Psychiatric Publishing, Inc; 2008: 1-31.
Critical Appraisal – Fundamental Concepts
Greenhalgh, T., Howick, J., Maskrey, N. (2014). Evidence based medicine: a
movement in crisis? BMJ, 348, g3725.
Murray, R.M. (2017). Mistakes I Have Made in My Research Career, Schizophrenia
Bulletin,43(2), 253-256
Ioannidis, J.P. (2017). Does evidence-based hearsay determine the use of medical
treatments? Social Science & Medicine, 177, 256-258
Simpkin, A.L., & Schwartzstein, R.M. (2016). Tolerating Uncertainty — The Next
Medical Revolution? NEJM, 375(18): 1713-1715
Thomas, P., Bracken, P., Timimi, S. (2012). The Limits of Evidence-Based Medicine in
Psychiatry. Philosophy, Psychiatry, & Psychology, 19(4), 295–308
Commercial Bias in Psychiatry Literature & Practice, And What You Can Do About It
Spielmans, G. I. & Parry, P. I. (2010). From Evidence-based Medicine to
Marketing-based Medicine: Evidence from Internal Industry Documents. Journal
of Bioethical Inquiry, 7, 13-29.
Schiff, G. D., Galanter, W. L., Duhig, J., Lodolce, A. E., Koronkowski, M. J., &
Lambert, B. L. (2011). Principles of conservative prescribing. Archives of Internal
Medicine, 171, 1433-1440.
Cosgrove, L., Vannoy, S., Mintzes, B., &Shaughnessy, A.F. (2016). Under the Influence:
The Interplay among Industry, Publishing, and Drug Regulation. Accountability in
Research 23(5), 257–79
Stamatakis, E., Weiler, R., & Ioannidis, J. P. A. (2013). Undue industry influences that
distort healthcare research, strategy, expenditure and practice: a review. European
journal of clinical investigation, 43(5), 469–475
Kendall, T. (2011). The rise and fall of the atypical antipsychotics. The British journal of
psychiatry: the journal of mental science, 199(4), 266–268
Mitigating Bias in Literature Evaluation
Keller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P., Birmaher, B. et
al. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a
randomized, controlled trial. J Am Acad.Child Adolesc.Psychiatry, 40, 762-772.
Jureidini, J.N., Amsterdam, J.D., McHenry, L.B. (2016). The citalopram CIT-MD-18
pediatric depression trial: Deconstruction of medical ghostwriting, data
mischaracterisation and academic malfeasance. The International Journal of Risk &
Safety in Medicine, 28(1), 33-43
= required reading = suggested reading 4
Ioannidis, J.P. (2016). Why Most Clinical Research Is Not Useful. PLoS Medicine, 13(6),
e1002049
Ghaemi, S. N. (2009). A Clinician’s Guide to Statistics and Epidemiology in Mental
Health: Measuring Truth and Uncertainty (1st ed.). Cambridge University Press
Greenhalgh, T. (2014). How to Read a Paper: The Basics of Evidence-Based Medicine
(5th ed.). BMJ Books
Moncrieff, J. & Cohen, D. (2009). How do psychiatric drugs work? BMJ, 338, b1963
Stimulants
Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-
term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One
2015; 10:e0116407.
Awudu GAH, Besag FMC. Cardiovascular effects of methylphenidate, amphetamines
and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Drug Saf 2014; 37:661-76.
Baweja R, Mattison RE, Waxmonsky JG. Impact of attention-deficit hyperactivity
disorder on school performance: what are the effects of medication? Pediatr Drugs 2015;
17:459-77.
Bélanger SA, Warren AE, Hamilton RM, Gray C, Gow RM, Sanatani S, et al. Cardiac
risk assessment before the use of stimulant medications in children and youth. Paediatr
Child Health 2009; 14:579-92.
Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF,
Bloch MH. Meta-analysis: risk of tics associated with psychostimulant use in
randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2015;
54:728-36.
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al.
Practitioner review: current best practice in the management of adverse events during
treatment with ADHD medications in children and adolescents. J Child Psychol
Psychiatry 2013; 54:227-46.
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH.
Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with
attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2015; 25:611-
7.
Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages,
disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;
48:240-8. (Read for third seminar on Stimulants.)
Hinshaw SP, Arnold LE; For the MTA Cooperative Group. ADHD, Multimodal
Treatment, and Longitudinal Outcome: Evidence, Paradox, and Challenge. Wiley
Interdiscip Rev Cogn Sci. 2015; 6:39-52.
= required reading = suggested reading 5
Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai G, Frati G, Romagnoli E, et al. Drugs
for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden
death in children: a meta-analysis of observational studies. Int J Cardiol 2013; 168:4320-
1.
Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA
at 8 years: prospective follow-up of children treated for combined-type ADHD in a
multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48:484-500.
Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and
other psychotic symptoms associated with the use of attention-deficit/hyperactivity
disorder drugs in children. Pediatrics 2009; 123:611-6.
The MTA Cooperative Group: A 14-month randomized clinical trial of treatment
strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;
56:1073-86. (Read for first seminar on Stimulants.)
Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, et al. A clinical review
of outcomes of the multimodal treatment study of children with attention-
deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep 2008; 10:424-3.
Parker J, Wales G, Chalhoub N, Harpin V. The long-term outcomes of interventions for
the management of attention-deficit hyperactivity disorder in children and adolescents: a
systematic review of randomized controlled trials. Psychol Res Behav Manag 2013;
17;6:87-99.
Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for
attention-deficit/hyperactivity disorder. Pediatrics 2008; 122:451-3.
Pliszka SR, AACAP Work Group on Quality Issues. AACAP Practice parameter for the
assessment and treatment of children and adolescents with attention-deficit/hyperactivity
disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894-921.
Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, Vohra S.
Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and
adolescents. Cochrane Database Syst Rev 2016 Feb 4;2:CD009996.
Schwarz A. A.D.H.D. Experts re-evaluate study’s zeal for drugs. The New York Times
(December 29, 2013).
Sharpe K. Medication: the smart-pill oversell. Nature 2014; 506:146-8.
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al.
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder
(ADHD). Cochrane Database Syst Rev 2015 Nov 25;(11):CD009885.
Swanson JM, Arnold LE, Molina BS, Sibley MH, Hechtman LT, Hinshaw SP, et al.
Young adult outcomes in the follow-up of the multimodal treatment study of
attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy,
and height suppression. J Child Psychol Psychiatry 2017, Epub ahead of print.
(Read for second seminar on Stimulants.)
Vaughan B. Kratochvil CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity
disorder. Child Adolesc Psychiatr Clin N Am 2012; 21:941-55.
= required reading = suggested reading 6
Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular
monitoring of children and adolescents with heart disease receiving medications for
attention deficit/hyperactivity disorder [corrected]: a scientific statement from the
American Heart Association Council on Cardiovascular Disease in the Young Congenital
Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation
2008; 117:2407-23.
Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity
disorder with respect to physical growth and cardiovascular function. Child Adolesc
Psychiatr Clin N Am 2008; 17:459-74.
Atomoxetine & Alpha-2 Agonists
Awudu GAH, Besag FMC. Cardiovascular effects of methylphenidate, amphetamines
and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Drug Saf 2014; 37:661-76.
Elbe D, Reddy D. Focus on guanfacine extended-release: a review of its use in child
and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2014; 23:48-50.
Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit
hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11:203-26.
Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity
disorder in youth: a systematic review and meta-analysis of monotherapy and add-on
trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014; 53:153-73.
Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of
α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related
disorders. J Child Adolesc Psychopharmacology 2013; 23:308-19.
Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents
with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis
and metaregression. J Am Acad Child Adolesc Psychiatry 2014;53:174-87.
The Tourette’s Syndrome Study Group: Treatment of ADHD in children with tics: a
randomized controlled trial. Neurology 2002; 58:527-36.
Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review:
pharmacological treatment of tic disorders—efficacy of antipsychotic and alpha-2
adrenergic agonist agents. Neurosci Biobehav Rev 2013; 37:1162-71.
Antipsychotics
Abidi S, Mian I, Garcia-Ortega I, Lecomte T, Raedler T, Jackson K, Jackson K,
Pringsheim T, Addington D. Canadian Guidelines for the Pharmacological
Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children
and Youth. Can J Psychiatry. 2017 Sep;62(9):635-647.
= required reading = suggested reading 7
Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M, MacGregor T,
Jafri SHA, Featherstone R, Hartling L. First- and Second-Generation
Antipsychotics in Children and Young Adults: Systematic Review Update.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Mar.
Gorman DA, Gardner DM, Murphy AL, Feldman M, Bélanger SA, Steele MM, Boylan
K, Cochrane-Brink K, Goldade R, Soper PR, Ustina J, Pringsheim T.
Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in
children and adolescents with attention-deficit hyperactivity disorder, oppositional
defiant disorder, or conduct disorder. Can J Psychiatry 2015;60(2):62–76
Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.
Atypical antipsychotics for psychosis in adolescents. Cochrane Database of Systematic
Reviews 2013, Issue 10. Art. No.: CD009582. DOI: 10.1002/14651858.CD009582.pub2.
Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of
oppositional behaviour, conduct problems, and aggression in children and adolescents
with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct
disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2
agonists, and atomoxetine. Can J Psychiatry. 2015 Feb;60(2):42-51.
Pringsheim T, Hirsch L, Gardner D, Gorman DA.
The pharmacological management of oppositional behaviour, conduct problems, and
aggression in children and adolescents with attention-deficit hyperactivity disorder,
oppositional defiant disorder, and conduct disorder: a systematic review and meta-
analysis. Part 2: antipsychotics and traditional mood stabilizers.
Can J Psychiatry. 2015 Feb;60(2):52-61.
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J.
Evidence-Based Recommendations for Monitoring Safety of Second Generation
Antipsychotics in Children and Youth.
The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in
Children (CAMESA) Guideline Project. J Can Acad Child Adolesc Psychiatry 2011
August; 20(3): 218-233.
Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al.
Double-blind comparison of first- and second-generation antipsychotics in early-onset
schizophrenia and schizo-affective disorder: findings from the treatment of early-onset
schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008
Nov;165(11):1420-31.
Book Chapters:
Clinical Handbook of Psychotropic Drugs for Children and Adolescents. 3rd Ed.
Elbe, Bezchlibnyk-Butler, Virani, Procyshyn (EDS.)
Antipsychotic Chapter (p.119-202).
Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
Stephen, Stahl Chapter 5: Antipsychotic Agents
= required reading = suggested reading 8
SSRIs
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to
another SSRI or to venlafaxine with or without cognitive behavioral therapy for
adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
JAMA2008 Feb 27;299(8):901-13.
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA:
Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric
antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;
297(15):1683-96
Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. Selective
serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without
cognitive behaviour therapy in adolescents with major depression: randomised controlled
trial. BMJ2007 Jul 21;335(7611):142
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M,
McNulty S, Vitiello B, Severe J: Fluoxetine, cognitive-behavioral therapy, and their
combination for adolescents with depression: Treatment for Adolescents With
Depression Study (TADS) randomized controlled trial. JAMA 2004; 292(7):807-20
(Read for first seminar on SSRIs.)
The POTS Team: Cognitive-behavior therapy, sertraline, and their combination for
children and adolescents with obsessive-compulsive disorder: the Pediatric OCD
Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292(16):1969-76
Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in
juvenile depression: meta-analysis. Br J Psychiatry2008 Jul;193(1):10-7
Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al.
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N
Engl J Med2008 Dec 25;359(26):2753-66. (Read for second seminar on SSRIs.)
Watson HJ, Rees CS. Meta-analysis of randomized, controlled treatment trials for
pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry2008 May;49(5):489-
98.
Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al.
Comparative efficacy and tolerability of antidepressants for major depressive disorder in
children and adolescents: a network meta-analysis. Lancet 2016; 388(10047):881-90.
Garland EJ, Kutcher S, Virani A, Elbe D. Update on the use of SSRIs and SNRIs with
children and adolescents in clinical practice (Position Paper). J Can Acad Child Adolesc
Psychiatry 2016; 25(1):4-10.
Ivarsson T, Skarphedinsson G, Kornør H, Axelsdottir B, Biedilæ S, Heyman I, et al. The
place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive
disorder (OCD) in children and adolescents: views based on a systematic review and
meta-analysis. Psychiatry Res 2015; 227(1):93-103.
= required reading = suggested reading 9
Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH.
Systematic review and meta-analysis: early treatment responses of selective serotonin
reuptake inhibitors in pediatric major depressive disorder. J Am Acad Child Adolesc
Psychiatry 2015; 54(7):557-64.
Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early
treatment responses of selective serotonin reuptake inhibitors and clomipramine in
pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2016;
55(10):851-859.
Walkup JT. Antidepressant efficacy for depression in children and adolescents: industry-
and NIMH-funded studies. Am J Psychiatry 2017; 174(5):430-437.
Other “New” Antidepressants
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching
to another SSRI or to venlafaxine with or without cognitive behavioral therapy for
adolescents with SSRI-resistant depression: the TORDIA randomized controlled
trial. JAMA2008 Feb 27;299(8):901-13.
Carlat D. Dr. Drug Rep. New York Times Magazine 2007:64-9.
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y: Venlafaxine ER for the treatment of
pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad
Child Adolesc Psychiatry 2007; 46(4):479-88
March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A Randomized controlled
trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol
Psychiatry2007 Nov 15;62(10):1149-54.
Rynn MA, Riddle MA, Yeung PP, Kunz NR: Efficacy and safety of extended-release
venlafaxine in the treatment of generalized anxiety disorder in children and adolescents:
two placebo-controlled trials. Am J Psychiatry 2007; 164(2):290-300
Placebo
Bingel U; Placebo Competence Team. Avoiding nocebo effects to optimize treatment
outcome. JAMA 2014; 312:693-4.
Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized
controlled trials of antidepressants for pediatric major depressive disorder. Am J
Psychiatry 2009; 166:42-9.
Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP.
Deconstructing pediatric depression trials: an analysis of the effects of expectancy and
therapeutic contact. J Am Acad Child Adolesc Psychiatry 2011; 50:782-95.
Murray D, Stoessl AJ. Mechanisms and therapeutic implications of the placebo
effect in neurological and psychiatric conditions. Pharmacol Ther. 2013;140(3):306-
18.
= required reading = suggested reading 10
Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, et al.
Characteristics of placebo responders in pediatric clinical trials of attention-
deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:1165-72.
Parellada M, Moreno C, Moreno M, Espliego A, de Portugal E, Arango C. Placebo effect
in child and adolescent psychiatric trials. Eur Neuropsychopharmacol 2012; 22:787-99.
Waschbusch DA, Pelham WE Jr, Waxmonsky J, Johnston C. Are there placebo effects in
the medication treatment of children with attention-deficit hyperactivity disorder? J Dev
Behav Pediatr 2009; 30:158-68.
Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label
placebo treatment in chronic low back pain: a randomized controlled trial. Pain.
2016;157(12):2766-2772
The Psychology of Psychopharmacology
Cabaniss DL: Shifting gears: The challenge to teach students to think psychodynamically
and pharmacologically at the same time. Psychoanal Inquiry 1998; 18: 639-656.
Chubinsky P, Hojman H. Psychodynamic perspectives on psychotropic medications for
children and adolescents. Child Adolesc Psychiatric Clin N Am 2013; 22:351-66.
Chubinsky P, Rappaport N. Medication and the fragile alliance: the complex meanings of
psychotropic medication to children, adolescents, and families. J Infant Child Adolesc
Psychother 2006; 5:111-23.
Floersch J, Towsend L, Longhofer J, et al. Adolescent experience of psychotropic
treatment. Transcult Psychiatry 2009; 46:157-79.
Kocsis JH, Leon AC, Markowitz JC, et al. Patient preference as a moderator of outcome
for chronic forms of major depressive disorder treated with nefazodone, cognitive
behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry
2009; 70:354-61.
Leuchter AF, Hunter AM, Tartter M, et al. Role of pill-taking, expectation and
therapeutic alliance in the placebo response in clinical trials for major depression. Br J
Psychiatry 2014;205:443-9.
Mallo CJ, Mintz DL. Teaching all the evidence bases: reintegrating psychodynamic
aspects of prescribing into psychopharmacology training. Psychodyn Psychiatry 2013;
41:13-37.
McKay KM, Imel ZE, Wampold BE. Psychiatrist effects in the psychopharmacological
treatment of depression. J Affect Disord 2006;92:287-90.
Mintz DL. Psychodynamic Trojan Horses: using psychopharmacology to teach
psychodynamics. J Am Acad Psychoanal Dyn Psychiatr 2006; 34:151-61.
Mintz DL. Teaching the prescriber's role: the psychology of psychopharmacology.
Acad Psychiatry 2005; 29:187-94.
= required reading = suggested reading 11
Mintz DL, Flynn DF. How (not what) to prescribe: nonpharmacologic aspects of
psychopharmacology. Psychiatr Clin North Am 2012; 35:143-63.
Perry S, Cooper AM, Michels R. The psychodynamic formulation: its purpose, structure,
and clinical application. Am J Psychiatry 1987; 144:543-50.
Pruett KD, Joshi SV, Martin A. Thinking about prescribing: the psychology of
psychopharmacology. In: Martin A, Scahill L, Kratochvil C eds. Pediatric
Psychopharmacology: Principles and Practice. 2nd ed. New York, NY: Oxford University
Press; 2011:422-33.
Rappoport N, Chubinsky P. The meaning of psychotropic medications for children,
adolescents, and their families. J Am Acad Child Adolesc Psychiatry 2000; 39:1198-
1200.
Rutherford BR, Wall MM, Brown PJ, Choo TH, Wager TD, Peterson BS, et al. Patient
expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J
Psychiatry 2017; 174:135-42.
Lithium
Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in
children. Int Rev Psychiatry2008 Apr;20(2):151-7
Blader JC. Another Look at the Treatment of Early-Age Mania (TEAM) Trial. Comment
in J Am Acad Child Adolesc Psychiatry 2013 February:52(2): 205-206
Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in
pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J
Am Acad Child Adolesc Psychiatry 2007; 46(6):687-700
Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and
tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of
acute, randomized, placebo-controlled trials, Bipolar Disord 2010; 12: 116-141.
Findling RL, Robb A, McNamara NK, Pavuluri M, Kafantaris V, Scheffer R et al.
Lithium in the Acute Treatment of Bipolar I Disorder: A Double-Blind, Placebo-
Controlled Study. Pediatrics 2015; 136(5): 885894.
Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, Heath J: Double-blind
and placebo-controlled study of lithium for adolescent bipolar disorders with secondary
substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37(2):171-8.
Geller B, Luby J, Joshi P, Wagner K, Emslie G, Walkup J et al. A Randomized
Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of
Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Arch Gen
Psychiatry 2012;69(5):515-528.
Gorman DA, Gardner GM, Murphy AL, Feldman M, Belanger SA, Steele MM et al.
Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in
Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional
Defiant Disorder, or Condcut Disorder. 2015; 60(2)62-76.
= required reading = suggested reading 12
Hall RC, Perl M, Pfefferbaum, B. Lithium Therapy and Toxicity. Am Fam Physician
1979 April 19(4):133-139.
Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M: Treatment
guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc
Psychiatry 2005; 44(3):213-35.
Landersdorfer CB, Findling LF, Frazier JA, Kafantaris V, Kirkpatrick CMJ. Lithium in
Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens
via Population Pharmacokinetics/Pharmacodynamics. Clin Pharmacokinet 2017; 56:77-
90.
Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR et al.
Pharmacologic Treatments for Pediatric Bipolar Disorder: A Review and Meta-
Analysis. J Am Acad Child Adolesc Psychiatry 2011 August;50(8);749-762.e39.
McClellan J, Commentary: Treatment Guidelines for Child and Adolescent Bipolar
Disorder. J Am Acad Child Adolesc Psychiatry 2005; 44(3):236-39.
Washburn JJ, West AE, Heil JA. Treatment of Pediatric Bipolar Disorder: A
Review. Minerva Psichiatr 2011 March; 52(1): 21-35.
Anticonvulsants
Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar disorder.
CNS Drugs2007;21(12):1019-33.
Biederman J, Joshi G. Mick E, Doyle R, Georgiopouls A, Hammerness P, Kotarski M,
Williams C, Wozniak j. A prospective open-label trail of lamotrigine monotherapy in
children and adolescents with bipolar disorder. CNS Neuroscience & Therapeutics 2010;
16:91-102
Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or
monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child
Adolesc Psychiatry2006 Mar;45(3):298-304Correll CU, Sheridan EM, DelBello MP:
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients
with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled
trials, Bipolar Disord 2010; 12: 116-141.
Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in
pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J
Am Acad Child Adolesc Psychiatry 2007; 46(6):687-700.
Findling RL, Chang K, Robb A, Foster VJ, Horrigan J, Krishen A et al. Adjunctive
Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled,
Randomized Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2015;
54(12):1020-1031.e3.
Geller B, Luby J, Joshi P, Wagner K, Emslie G, Walkup J et al. A Randomized
Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of
= required reading = suggested reading 13
Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Arch Gen
Psychiatry 2012;69(5):515-528.
Gorman DA, Gardner GM, Murphy AL, Feldman M, Belanger SA, Steele MM et al.
Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in
Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional
Defiant Disorder, or Condcut Disorder. 2015; 60(2)62-76.
Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice.
Expert opin Drug Metab Toxicol 2009; 5(5): 539-551
Hamrin V, DeSanto Iennaco, J. Psychopharmacology of pediatric bipolar disorder. Expert
Rev Neurother 2010; 10(7), 1053-1088
Joshi G, Wozniak J, Mick E, Doyle R, Hammerness P, Geogiopolous A, Kotarski M,
Aleardi M, Williams C, Walls S, Biederman J. A prospective open label trial of extended-
release carbamazepine monotherapy in children with bipolar disorder. J of Child and
Adolesc Psychopharm 2010; 20(1):7-14
Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, Keller MB.
Antiepileptic Drugs for Bipolar Disorder and the Risk of Suicidal Behavior: A 30-Year
Observational Study Am J Psychiatry 2012 March169(3):285-291
Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP et al.
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis
in children: a pooled analysis. Pediatrics 2009 Feb;123(2):e297-304
Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR et al.
Pharmacologic Treatments for Pediatric Bipolar Disorder: A Review and Meta-
Analysis. J Am Acad Child Adolesc Psychiatry 2011 August;50(8);749-762.e39
Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et al. A
double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of
bipolar disorder in children and adolescents. Am J Psychiatry2006 Jul;163(7):1179-86.
Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, Wozniak P, Vigna
NV, Abi-Saab W, Saltarelli M. A double-blind, placebo-controlled trial of divalproex
extended-release in the treatment of bipolar disorder in children and adolescents. J Am
Acad Child Adolesc Psychiatry 2009; 48(5):519-532
Washburn JJ, West AE, Heil JA. Treatment of Pediatric Bipolar Disorder: A
Review. Minerva Psichiatr 2011 March; 52(1): 21-35
Psychopharmacology in Autism Spectrum Disorders
Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al.;
Research Units on Pediatric Psychopharmacology Autism Network. Medication and
parent training in children with pervasive developmental disorders and serious
behavior problems: results from a randomized clinical trial. J Am Acad Child
Adolesc Psychiatry 2009; 48:1143-54.
= required reading = suggested reading 14
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic treatment of repetitive behaviors in
autism spectrum disorders: evidence of publication bias. Pediatrics 2012; 129:e1301-10.
Elbe D, Lalani Z. Review of the pharmacotherapy of irritability of autism. J Can Acad
Child Adolesc Psychiatry 2012; 21:130-46.
Ghanizadeh A. Atomoxetine for treating ADHD symptoms in autism: a systematic
review. J Atten Disord 2013; 17:635-40.
Handen BL, Taylor J, Tumuluru R. Psychopharmacological treatment of ADHD
symptoms in children with autism spectrum disorder. Int J Adolesc Med Health 2011;
23:167-73.
Smith T, Aman MG, Arnold LE, Silverman LB, Lecavalier L, Hollway J, Tumuluru
R, Hyman SL, Buchan-Page KA, Hellings J, Rice RR Jr, Brown NV, Pan X, Handen BL.
Atomoxetine and Parent Training for Children With Autism and
Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. J Am Acad
Child Adolesc Psychiatry. 2016 Oct;55(10):868-876.e2. doi:
10.1016/j.jaac.2016.06.015. Epub 2016 Aug 2. PubMed PMID: 27663942; PubMed
Central PMCID: PMC5108566.
Handen BL, Aman MG, Arnold LE, Hyman SL, Tumuluru RV, Lecavalier L,
Corbett-Dick P, Pan X, Hollway JA, Buchan-Page KA, Silverman LB, Brown NV, Rice
RR Jr, Hellings J, Mruzek DW, McAuliffe-Bellin S, Hurt EA, Ryan MM, Levato L,
Smith T. Atomoxetine, Parent Training, and Their Combination in Children With
Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. J Am Acad
Child Adolesc Psychiatry. 2015 Nov;54(11):905-15. doi: 10.1016/j.jaac.2015.08.013.
Epub 2015 Sep 3. PubMed PMID: 26506581; PubMed
Central PMCID: PMC4625086.
Tumuluru RV, Corbett-Dick P, Aman MG, Smith T, Arnold LE, Pan X, Buchan-Page
KA, Brown NV, Ryan MM, Hyman SL, Hellings J, Williams C, Hollway JA, Lecavalier
L, Rice RR Jr, McAuliffe-Bellin S, Handen BL. Adverse Events of Atomoxetine in a
Double-Blind Placebo-Controlled Study in Children with Autism. J Child Adolesc
Psychopharmacol. 2017 May 16. doi: 10.1089/cap.2016.0187. [Epub ahead of print]
PubMed PMID: 28509573.
King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al.; STAART
Psychopharmacology Network. Lack of efficacy of citalopram in children with autism
spectrum disorders and high levels of repetitive behavior: citalopram ineffective in
children with autism. Arch Gen Psychiatry 2009; 66:583-90.
Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-
controlled, fixed-dose study of aripiprazole in children and adolescents with irritability
associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:1110-9.
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al.; Research
Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with
autism and serious behavioral problems. N Engl J Med 2002; 347:314-21.
= required reading = suggested reading 15
Research Units on Pediatric Psychopharmacology Autism Network. Randomized,
controlled, crossover trial of methylphenidate in pervasive developmental disorders with
hyperactivity. Arch Gen Psychiatry 2005; 62:1266-74.
Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors
(SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010; Issue
8. Art. No.: CD004677.
Young NJ, Findling RL. An update on pharmacotherapy for autism spectrum disorder in
children and adolescents. Curr Opin Psychiatry 2015; 28:91-101.
Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R,
Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle
J; Research Units on Pediatric Psychopharmacology Autism Network.
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum
Disorder. Am J Psychiatry. 2015 Dec;172(12):1197-206. doi:
10.1176/appi.ajp.2015.15010055. Epub 2015 Aug 28. PubMed PMID: 26315981.
Psychopharmacology for Sleep and Agitation
Gruber R, Carrey N, Weiss SK, Frappier JY, Rourke L, Brouillette RT, Wise MS.
Position statement on pediatric sleep for psychiatrists. J Can Acad Child Adolesc
Psychiatry 2014; 23:174-95.
Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB.
Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset
insomnia. J Am Acad Child Adolesc Psychiatry 2007; 46:233-41.
Owens JA. Pharmacotherapy of pediatric insomnia. J Am Acad Child Adolesc Psychiatry
2009; 48:99-107.
Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia
associated with attention-deficit/hyperactivity disorder. Pediatrics 2014; 134:e1095-103.
Pelayo R1, Yuen K. Pediatric sleep pharmacology. Child Adolesc Psychiatr Clin N Am
2012; 21:861-83.
Maski K, Owens JA. Insomnia, parasomnias, and narcolepsy in children: clinical
features, diagnosis, and management. Lancet Neurol 2016; 15:1170-81.
Carubia B, Becker A, Levine BH. Child Psychiatric Emergencies: Updates on
Trends, Clinical Care, and Practice Challenges. Curr Psychiatry Rep 2016; 18:41
Hilt RJ, Woodward TA. Agitation treatment for pediatric emergency patients. J Am Acad
Child Adolesc Psychiatry 2008; 47:132-8.
Allison L, Moncrieff J. 'Rapid tranquillisation': an historical perspective on its emergence
in the context of the development of antipsychotic medications. Hist Psychiatry 2014;
25:57-69.
= required reading = suggested reading 16
Gorman DA, Gardner DM, Murphy AL, Feldman M, Bélanger SA, Steele MM, Boylan
K, Cochrane-Brink K, Goldade R, Soper PR, Ustina J, Pringsheim T. Canadian
guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and
adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or
conduct disorder. Can J Psychiatry 2015; 60:62-76.
Turkel SB, Hanft A. The pharmacologic management of delirium in children and
adolescents. Paediatr Drugs 2014; 16:267-74.
Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A,
Veenstra-Vanderweele J, Hardan AY. Pharmacologic Treatment of Severe Irritability and
Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics. 2016;
137:S124-35.
Benarous X, Consoli A, Guilé JM, Garny de La Rivière S, Cohen D, Olliac B. Evidence-
based treatments for youths with severely dysregulated mood: a qualitative systematic
review of trials for SMD and DMDD. Eur Child Adolesc Psychiatry 2017; 26:5-23.
Gurnani T, Ivanov I, Newcorn JH. Pharmacotherapy of Aggression in Child and
Adolescent Psychiatric Disorders. J Child Adolesc Psychopharmacol 2016; 26:65-73.
Cummings MR, Miller BD. Pharmacologic management of behavioral instability in
medically ill pediatric patients. Curr Opin Pediatr 2004; 16:516-22.
Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, Crystal S, Jensen PS; Treatment
of Maladaptive Aggressive in Youth Steering Committee. Treatment of maladaptive
aggression in youth: CERT guidelines II. Treatments and ongoing management.
Pediatrics 2012; 129:e1577-86.
Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, Jensen PS.
Experts' recommendations for treating maladaptive aggression in youth. J Child Adolesc
Psychopharmacol 2011; 21:505-15.
Appendix
Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA, et al. A pilot
controlled trial of topiramate for mania in children and adolescents with bipolar disorder.
J Am Acad Child Adolesc Psychiatry 2005; 44:539-47.
Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic
antidepressant use in children and adolescents. J Am Acad Child Adolesc
Psychiatry1999; 38:513-6.
Grady MM, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and
removing barriers. CNS Spectr 2012; 17:2-10.
Mancuso CE, Tanzi MG, Gabay M: Paradoxical reactions to benzodiazepines: literature
review and treatment options. Pharmacotherapy 2004; 24:1177-85.
Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention
deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database
Syst Rev 2014, Issue 9.
= required reading = suggested reading 17
Witek MW, Rojas V, Alonso C, Minami H, Silva RR: Review of benzodiazepine use in
children and adolescents. Psychiatr Q 2005; 76:283-96.
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Modafinil for the
treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Psychiatr Res
2017; 84:292-300.